JS212 and JS111 for advanced lung cancer with EGFR mutations
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Confirmed non-squamous lung cancer that is advanced (spread to other parts of body) and cannot be surgically removed
- Your cancer has a specific EGFR gene mutation (exon 19 deletion, L858R, or similar variants)
- You have received prior EGFR-targeted therapy and your cancer has grown despite treatment
- Good overall health and organ function (blood counts, liver, kidney, and heart function within acceptable ranges)
- Not pregnant or breastfeeding, and willing to use birth control during and after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
This trial tests a new drug called JS212 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can help shrink tumors.
This trial tests a new drug called JS212 in combination with other medicines for people with metastatic colorectal cancer that has not been treated before. It focuses on patients whose tumors are MSS or pMMR and aims to see if these combinations are safe and effective.
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This trial tests two experimental drugs, JS212 and JS111, as a first treatment for advanced lung cancer with a specific EGFR mutation. It aims to see if the combination can shrink tumors and help people live longer.
Hear when a new Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.